Clarient Licenses Biomarker for Cancer Dx, Theranostics

Clarient plans to develop a test for diagnosting, selecting therapy, and monitoring drug response in cancer patients.

Full-text access for registered users only. Existing users login here.
New to GenomeWeb? Register quickly here for free access.